Skip navigation
Skip navigation

Short-Term Therapy with Peroxisome Proliferation-Activator Receptor-Agonist Wy-14,643 Protects Murine Fatty Liver Against Ischemia-Reperfusion Injury

Teoh, Narcissus; Williams, Jacqueline; Hartley, Jennifer; Yu, Jun; McCuskey, Robert; Farrell, Geoffrey

Description

Steatosis increases operative morbidity/mortality from ischemia-reperfusion injury (IRI); few pharmacological approaches have been protective. Using novel genetic/dietary models of nonalcoholic steatohepatitis (NASH) and simple steatosis (SS) in Alms1 mutant (foz/foz) mice, we characterized severity of IRI in NASH versus SS and lean liver and tested our hypothesis that the lipid-lowering effects of the peroxisome proliferation-activator receptor (PPAR)-agonist Wy-14,643 would be...[Show more]

dc.contributor.authorTeoh, Narcissus
dc.contributor.authorWilliams, Jacqueline
dc.contributor.authorHartley, Jennifer
dc.contributor.authorYu, Jun
dc.contributor.authorMcCuskey, Robert
dc.contributor.authorFarrell, Geoffrey
dc.date.accessioned2015-12-10T23:19:54Z
dc.identifier.issn0270-9139
dc.identifier.urihttp://hdl.handle.net/1885/66097
dc.description.abstractSteatosis increases operative morbidity/mortality from ischemia-reperfusion injury (IRI); few pharmacological approaches have been protective. Using novel genetic/dietary models of nonalcoholic steatohepatitis (NASH) and simple steatosis (SS) in Alms1 mutant (foz/foz) mice, we characterized severity of IRI in NASH versus SS and lean liver and tested our hypothesis that the lipid-lowering effects of the peroxisome proliferation-activator receptor (PPAR)-agonist Wy-14,643 would be hepatoprotective. Mice were subjected to 60-minute partial hepatic IRI. Microvascular changes were assessed at 15-minute reperfusion by in vivo microscopy, injury at 24 hours by serum alanine aminotransferase (ALT), and hepatic necrosis area. Injury and inflammation mediators were determined by way of immunoblotting for intercellular cellular adhesion molecule, vascular cellular adhesion molecule, p38, c-jun N-terminal kinase, IB-, interleukin (IL)-1a, IL-12, tumor necrosis factor-(TNF-) and IL-6, cell cycle by cyclin D1 and proliferating cell nuclear antigen immunohistochemistry. In foz/foz mice fed a high-fat diet (HFD) to cause NASH or chow (SS), IRI was exacerbated compared with HFD-fed or chow-fed wild-type littermates by ALT release; corresponding necrotic areas were 60 22%NASH, 29 9%SS versus 7 1%lean. Microvasculature of NASH or SS livers was narrowed by enormous lipid-filled hepatocytes, significantly reducing numbers of perfused sinusoids, all exacerbated by IRI. Wy-14,643 reduced steatosis in NASH and SS livers, whereas PPAR-stimulation conferred substantial hepatoprotection against IRI by ALT release, with reductions in vascular cellular adhesion molecule-1, IL-1a, TNF-, IL-12, activated nuclear factor-B (NF-B), p38, IL-6 production and cell cycle entry. Conclusion: NASH and SS livers are both more susceptible to IRI. Mechanisms include possible distortion of the microvasculature by swollen fat-laden hepatocytes, and enhanced production of several cytokines. The beneficial effects of Wy-14,643 may be exerted by dampening adhesion molecule and cytokine responses, and activating NF-B, IL-6 production, and p38 kinase to effect cell cycle entry.
dc.publisherW B Saunders Co
dc.sourceHepatology
dc.subjectKeywords: alanine aminotransferase; autacoid; cyclin D1; cycline; I kappa B alpha; immunoreactive insulin; interleukin 12; interleukin 1alpha; interleukin 6; mitogen activated protein kinase p38; peroxisome proliferator activated receptor alpha agonist; pirinixic a
dc.titleShort-Term Therapy with Peroxisome Proliferation-Activator Receptor-Agonist Wy-14,643 Protects Murine Fatty Liver Against Ischemia-Reperfusion Injury
dc.typeJournal article
local.description.notesImported from ARIES
local.identifier.citationvolume51
dc.date.issued2010
local.identifier.absfor110307 - Gastroenterology and Hepatology
local.identifier.ariespublicationf2965xPUB1217
local.type.statusPublished Version
local.contributor.affiliationTeoh, Narcissus, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationWilliams, Jacqueline, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationHartley, Jennifer, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationYu, Jun, Chinese University of Hong Kong
local.contributor.affiliationMcCuskey, Robert, University of Arizona
local.contributor.affiliationFarrell, Geoffrey, College of Medicine, Biology and Environment, ANU
local.description.embargo2037-12-31
local.bibliographicCitation.issue3
local.bibliographicCitation.startpage996
local.bibliographicCitation.lastpage1006
local.identifier.doi10.1002/hep.23420
dc.date.updated2016-02-24T08:10:27Z
local.identifier.scopusID2-s2.0-77950600111
local.identifier.thomsonID000275472300030
CollectionsANU Research Publications

Download

File Description SizeFormat Image
01_Teoh_Short-Term_Therapy_with_2010.pdf3.61 MBAdobe PDFThumbnail


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  17 November 2022/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator